Download Evaluation report - Virology Education

14TH EUROPEAN MEETING ON
HIV&HEPATITIS
TREATMENT STRATEGIES & ANTIVIRAL DRUG RESISTANCE
ROME, ITALY • 25 - 27 MAY 2016
EVALUATION REPORT
www.virology-education.com
EXECUTIVE SUMMARY
The 14TH EUROPEAN MEETING ON VIRAL HEPATITIS AND CO-INFECTION WITH HIV was held on 25- 27 May 2016 at the Roma
Eventi Fontana di Trevi Conference Centre and was attended by nearly 300 participants from 40 countries. The meeting
gathers a steady international community of researchers and healthcare professionals. The population of this meeting
has been stable for a few consecutive years. In 2016 it was almost identical to that of last year.
Professional background of the participants is reflected in the below chart:
Professional Background
Virologist
1%
PhD
Student
8%
Other
16%
Clinician
31%
Lab technician
5%
Researcher
39%
“A unique forum for
improved management
and monitoring of HIV and
Hepatitis infected patients in
Europe, with evidence-based
recommendations.”
IMPACT
97% of the respondents indicated that the content of the workshop increased their knowledge, and 83% indicated that
the workshop is beneficial for the clinical management of their patients. Furthermore, 86% of the respondents indicated
that they intend to incorporate the new information into their daily practice after attending the workshop.
On average, 90% of the respondents indicated that the learning objectives were met.
PROGRAM
The program included 18 invited lectures, 20 oral abstract presentations, two guided poster tours - in addition to
the regular poster viewing sessions, a pro-con debate and two roundtable discussions. Ample time was allocated
for discussion. Just as last year, 3/4 day was dedicated to Hepatitis C resistance, by way of incorporating the 11th
International Workshop on Hepatitis C: Resistance and New Compounds. The presentation of Dr. Francesca Ceccherini,
entitled What do we know about RAVs today (delivered as part of the HCV Resistance meeting) received the highest score
(an average of 4,7 (out of 5)) on all categories.
GENERAL MEETING SCORE
93% of the participants rated the meeting experience as excellent/good. 97% would recommend this meeting to their
peers and 85% intend to attend next year.
30% indicated good experience by previous editions as one of the main reasons to attend the workshop.
The Organizing Committee and the Organizing Secretariat are pleased with the evaluation results of the 14th edition of this
meeting and are looking forward to an even more successful edition in 2017!
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
2
CONTENT
Executive Summary............................................................................... 2
Introduction............................................................................................ 4
Background..............................................................................................4
Unique Meeting Features........................................................................4
Target Audience.......................................................................................4
CME Accreditation...................................................................................4
Meeting Objectives...................................................................................5
Learning Objectives.................................................................................5
Meeting Partners................................................................................... 6
Commercial Supporters........................................................................ 7
Organizing Committee........................................................................... 8
Scientific Committee ...........................................................................10
Participants’ Feedback.........................................................................12
Learning Objectives...............................................................................12
General Event Experience.....................................................................12
Lectures.................................................................................................13
Guided Poster Tour................................................................................18
Organization...........................................................................................19
Publicity.................................................................................................19
Meeting demographics.........................................................................20
Number of Participants.........................................................................20
Professional Background......................................................................20
Conclusion............................................................................................21
List of Participants................................................................................22
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
3
INTRODUCTION
This is the evaluation report of the 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance,
held on 25 - 27 May 2016 at the Roma Eventi - Fontana di Trevi Conference Center. The Organizing Commitee and the Organizing
Secretariat highly value the opinion of the participants in order to further improve the quality of the workshop. Participants were
asked to complete an evaluation form to share their opinion on several subjects. Average response rate to this survey was 50%.
BACKGROUND
The European HIV and Hepatitis meeting was started 14 years ago with the objective to provide infectious disease clinicians
and clinical virologists involved in clinical practice and research with an opportunity to share data and discuss their clinical
application. Originally the focus was on HIV but over the years with the developments in the viral hepatitis field HCV and
HBV were added. The focus for each of these infections is on treatment of mono - infection.
In the last decade the meeting has been able to capture a constant group of leading clinicians and researchers from
Europe. As such, this meeting is the only European platform where infectious disease doctors and clinical virologists get
together on an annual basis to have more in depth discussions regarding the developments in antiviral therapy.
FORMAT
This 2,5 day international, abstract-driven scientific and educational workshop consisted of invited lectures, round-table
discussions, abstract- driven presentations and poster sessions. In order to ascertain an interactive workshop setting,
much time was allocated to discussions. From 2015, the meeting incorporates the International Workshop on Hepatitis C:
Resistance and New Compounds as a half-day program on Day 2.
UNIQUE MEETING FEATURES
The European Meeting on HIV & Hepatitis – Treatment Strategies & Antiviral Drug Resistance is a unique European platform
for clinicians and clinical virologists to discuss the latest developments in antiviral therapy for HIV, HCV and HBV and for
translating them into new treatment strategies to further improve clinical care.
TARGET AUDIENCE
•
Clinicians involved in daily care of individuals infected with HIV, HCV and HBV;
•
Scientists involved in antiviral drug development;
•
Researchers;
•
Post-graduate students.
CME ACCREDITATION
The 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance was designated for a
maximum of 15 hours of European external CME credits.
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
4
INTRODUCTION
MEETING OBJECTIVES
•
To gather professionals in the field of infectious diseases and clinical virology in an interactive workshop setting;
•
To provide a platform for presentation and discussion of the latest developments in the field of antiviral drug
development;
•
To map all current studies and results;
•
To translate new data to treatment guidelines;
•
To educate clinicians on how to best implement current and new drugs in clinical practice.
LEARNING OBJECTIVES
After participating in this activity, the participants will:
•
Have a thorough knowledge of the most recent results in drug development (including most recent clinical trials
results) for HIV, HCV and HBV;
•
Be able to integrate the latest scientific results into daily clinical care to improve the quality of life of HIV / Hepatitis
infected individuals;
•
Recognize the future challenges in screening, monitoring and diagnosis of HIV and of HCV or HBV infected patients.
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
5
MEETING PARTNERS
IN COLLABORATION WITH
UNDER THE AUSPICES OF
ENDORSED BY
ACADEMIC SUPPORTERS
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
6
COMMERCIAL SUPPORTERS
Financial support for the 14TH EUROPEAN MEETING ON HIV & HEPATITIS - TREATMENT STRATEGIES & ANTIVIRAL DRUG
RESISTANCE was provided by the following companies:
TITANIUM LEVEL
GOLD LEVEL
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
7
ORGANIZING COMMITTEE
CHARLES BOUCHER, MD,
PHD
FRANCESCA CECCHERINI
- SILBERSTEIN, PHD
Erasmus Medical
Center, Rotterdam, the
Netherlands
University of Rome “Tor
Vergata”, Italy
STÉPHANE CHEVALIEZ,
PHARMD, PHD
ANDREA DE LUCA, MD
Hôpital Henri Mondor,
Université Paris XII,
Paris, France
Catholic University of the
Sacred Heart, Rome and
University Hospital of
Siena, Italy
STEPHAN DRESSLER, MD,
PHD
ANNA-MARIA GERETTI,
MD, PHD
European AIDS
Treatment Group,
Berlin, Germany
University of Liverpool,
Institute of Infection and
Global Health, Liverpool, UK
ROGER PAREDES, MD,
PHD
JEAN-MICHEL
PAWLOTSKY, MD, PHD
Irsi Caixa Foundation,
Barcelona, Spain
Hôpital Henri Mondor,
Université Paris XII,
Paris, France
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
8
ORGANIZING COMMITTEE
CARLO FEDERICO PERNO,
MD, PHD
JONATHAN SCHAPIRO,
MD
University of Rome “Tor
Vergata “, Rome, Italy
Sheba Medical Center,
Tel Aviv, Israel
ANNE - MIEKE
VANDAMME, PHD
LINOS VANDEKERCKHOVE,
MD, PHD
Katholieke Universiteit
Leuven, Belgium
University Hospital of
Gent, Belgium
JENS VERHEYEN, MD
ANNEMARIE WENSING,
MD, PHD
University Clinic Essen,
Germany
University Medical
Centre Utrecht, the
Netherlands
STEFAN ZEUZEM, MD
J.W. Goethe University
Hospital, Frankfurt,
Germany
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
9
SCIENTIFIC COMMITTEE
Jan Albert, MD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . IMPI Karolinska Institute, Sweden
Claudia Balotta, MD. . . . . . . . . . . . . . . . . . . . . . . . . University of Milan, Italy
Carlos Beltran, MD . . . . . . . . . . . . . . . . . . . . . . . . . Chilean AIDS Group, Chile
Marina Bobkova, PhD . . . . . . . . . . . . . . . . . . . . . . Ivanovsky Institute of Virology, Russia
Ricardo Camacho, PhD. . . . . . . . . . . . . . . . . . . . . . Hospital Egas Moniz, Portugal
Bonaventura Clotet, MD, PhD. . . . . . . . . . . . . . . . . Irsi Caixa Foundation, Barcelona, Spain
Rolf Kaiser, PhD. . . . . . . . . . . . . . . . . . . . . . . . . . . . University of Cologne, Germany
Leon Kostrikis, PhD. . . . . . . . . . . . . . . . . . . . . . . . . University of Cyprus, Cyprus
Clive Loveday, PhD. . . . . . . . . . . . . . . . . . . . . . . . . . ICVC Charitable Trust, Clinical Virology, United Kingdom
Jens Lundgren, MD. . . . . . . . . . . . . . . . . . . . . . . . . National University Hospital & University of Copenhagen, Denmark
Anne-Genevieve Marcelin, PharmD, PhD. . . . . . . UPMC, France
Claus Nielsen, MD, PhD . . . . . . . . . . . . . . . . . . . . . Statens Serum Institut, Denmark
Monique Nijhuis, PhD. . . . . . . . . . . . . . . . . . . . . . . University Medical Center Utrecht, The Netherlands
Dimitris Paraskevis, PhD . . . . . . . . . . . . . . . . . . . . University of Athens, Medical School, Greece
Mario Poljak, MD, PhD. . . . . . . . . . . . . . . . . . . . . . Institute for Microbiology and Immunology, Slovenia
Elisabeth Puchhammer, MD. . . . . . . . . . . . . . . . . . University of Vienna, Austria
Jürgen Rockstroh, MD. . . . . . . . . . . . . . . . . . . . . . University of Bonn, Germany
Christophe Rodriguez, MD . . . . . . . . . . . . . . . . . . . Hôpital Henri Mondor, France
Gary Rubin, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . University of Toronto, Canada
Jean- Claude Schmit, MD, PhD . . . . . . . . . . . . . . . Centre Hospitalier de Luxembourg & CRP-Santé, Luxembourg
Rob Schuurman, PhD . . . . . . . . . . . . . . . . . . . . . . . University Medical Centre Utrecht, The Netherlands
Anders Sönnerborg, MD, PhD . . . . . . . . . . . . . . . . Karolinska Institut, Sweden
Vincent Soriano, MD, PhD. . . . . . . . . . . . . . . . . . . . Hospital Carlos III, Spain
Janusz Stanczak, PhD. . . . . . . . . . . . . . . . . . . . . . . University of Warsaw, Poland
Adrian Streinu - Cercel, MD, PhD . . . . . . . . . . . . . National Institute of Inf. Diseases “Prof.Dr. Matei Bals”, Romania
Hauke Walter, MD. . . . . . . . . . . . . . . . . . . . . . . . . . Medizinisches Labor Dr. Berg, Germany
Maurizio Zazzi, PhD . . . . . . . . . . . . . . . . . . . . . . . . University of Siena, Italy
Fabien Zoulim, MD, PhD . . . . . . . . . . . . . . . . . . . . INSERM, France
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
10
COMMITTEES
11TH INTERNATIONAL WORKSHOP ON HEPATITIS C: RESISTANCE
AND NEW COMPOUNDS
ORGANIZING COMMITTEE
CHARLES BOUCHER, MD,
PHD
Erasmus Medical
Center, Rotterdam, the
Netherlands
STÉPHANE CHEVALIEZ,
PHARMD, PHD
Hôpital Henri Mondor,
Université Paris XII,
Paris, France
ANITA HOWE, PHD
British Columbia Center
for Excellence for HIV/
AIDS, Canada
STEFAN ZEUZEM, MD
J.W. Goethe University
Hospital, Frankfurt,
Germany
SCIENTIFIC COMMITTEE
Ralf Bartenschlager, PhD . . . . . . . . . . . . . . . . . . . University of Heidelberg, Germany
Francesca Ceccherini-Silverstein, PhD . . . . . . . . University of Rome, Italy
Raffaele De Francesco, PhD . . . . . . . . . . . . . . . . . Fondazione INGM, Italy
Jeffrey Glenn, MD, PhD. . . . . . . . . . . . . . . . . . . . . . Stanford University, USA
Eric Hughes, MD, PhD. . . . . . . . . . . . . . . . . . . . . . . Bristol-Myers Squibb Company, USA
George Kukolj, PhD. . . . . . . . . . . . . . . . . . . . . . . . . Boehringer Ingelheim, Canada
Michael Manns, MD. . . . . . . . . . . . . . . . . . . . . . . . . Medical School of Hannover, Germany
Isabel Najera, PhD. . . . . . . . . . . . . . . . . . . . . . . . . . Roche (Palo Alto), USA
Jean-Michel Pawlotsky, MD, PhD . . . . . . . . . . . . . Hôpital Henri Mondor, France
Chris Petropoulos, PhD. . . . . . . . . . . . . . . . . . . . . . Monogram Biosciences, USA
Tami Pilot-Matias, PhD. . . . . . . . . . . . . . . . . . . . . . Abbvie, USA
Charles Rice, PhD. . . . . . . . . . . . . . . . . . . . . . . . . . Rockefeller University, USA
Celia Schiffer, PhD. . . . . . . . . . . . . . . . . . . . . . . . . . University of Massachusetts, USA
Robert Schooley, MD . . . . . . . . . . . . . . . . . . . . . . . University of California, USA
David Standring, PhD
Mark Sulkowski, MD. . . . . . . . . . . . . . . . . . . . . . . . Johns Hopkins University, USA
Bill Symonds, PharmD . . . . . . . . . . . . . . . . . . . . . . Roivant Sciences, USA
Takaji Wakita MD, PhD . . . . . . . . . . . . . . . . . . . . . . National Institute of Infectious Diseases, Japan
11th International Workshop on Hepatitis C: Resistance and New Compounds
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral
Drug
Resistance
26 May
2016,
Rome, Italy
25 - 27 May 2016, Rome, Italy
11
11
PARTICIPANTS’ FEEDBACK
INTENT TO CHANGE
(Strongly) agree
Neutral
(Strongly) disagree
The lectures have increased my knowledge of
treatment strategies and antiviral drug resistance
97%
3%
0%
This program is beneficial for the clinical
management of my patients
83%
17%
0%
I intend to incorporate the new information into the
care of my patients
86%
9%
5%
The following factor(s) might prevent me from implementing the gained knowledge:
My patient population might not be appropriate for the implementation.
22%
My current office and practice systems might not accommodate the changes.
33%
My patients might have trouble complying with these changes/ strategies.
11%
The medications/ procedures discussed might not be available for my patients.
22%
These changes might be too time consuming.
11%
LEARNING OBJECTIVES
(Strongly) agree
Average
(Strongly) disagree
Have a thorough knowledge of the most recent
results in drug development (including most recent
clinical trials results) for HIV, HCV and HBV
93%
7%
0%
Be able to integrate the latest scientific results into
daily clinical care to improve the quality of life of HIV
/ Hepatitis infected individuals
86%
14%
0%
Excellent /very much
Average/neutral
Fair /disagree
After completing this activity, the participants will:
GENERAL EVENT EXPERIENCE
agree
Overall event experience
93%
7%
0%
Opportunity of networking
93%
7%
0%
Content of the conference
93%
7%
0%
Number of invited lectures versus abstracts
79%
21%
0%
Was Hep C resistance a valuable addition to the
meeting?
93%
3%
2%
Time allocation for discussion
100%
0%
0%
Time allocation per presentation
93%
3%
2%
No commercial bias (product selling) perceived
85%
11%
4%
I would recommend this meeting to my peers
97%
3%
0%
I plan to attend this meeting next year
85%
15%
0%
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
12
PARTICIPANTS’ FEEDBACK
LECTURES
WEDNESDAY 25 MAY
HIV in Europe 2020 – what will it look like?
Carlo Federico Perno, MD, PhD, University
of Rome “Tor Vergata”, Italy
Excellent / Good
Average
Fair / poor
Interesting
99%
1%
0%
Relevance
88%
7%
5%
Performance
93%
6%
1%
Session 1: Early ARV treatment: start early, but not
too early
Life-long therapy
Georg Behrens, MD, PhD, Medical School
Hannover, Germany
Excellent / Good
Average
Fair / poor
Interesting
91%
9%
0%
Relevance
82%
16%
2%
Performance
87%
11%
2%
Excellent / Good
Average
Fair / poor
Interesting
85%
15%
0%
Relevance
70%
22%
8%
Abstract-driven presentations:
Potent Activity of GS-9883, a Novel Unboosted HIV-1
Integrase Strand Transfer Inhibitor (INSTI), Against
Patient Isolates with INSTI-Resistance
K. White O_01
Dolutegravir plus Rilpivirine in cART-Experienced
Subjects: a cohort study
G. Sterrantino O_02
Dolutegravir plus Ritonavir-Boosted Darunavir in Highly
cART-Experienced Subjects
G. Sterrantino O_03
Excellent / Good
Average
Fair / poor
Interesting
72%
18%
10%
Relevance
61%
21%
18%
Excellent / Good
Average
Fair / poor
Interesting
73%
15%
12%
Relevance
60%
19%
21%
Excellent / Good
Average
Fair / poor
Interesting
78%
19%
3%
Relevance
67%
25%
8%
Session 2: Spread of HIV drug resistance
Abstract-driven presentations:
Next generation sequencing in routine HIV-1 resistance
diagnostic - frequency of additional resistance relevant
mutations in 2% and 1% population proportions
R. Ehret O_04
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
13
PARTICIPANTS’ FEEDBACK
3 Transmission of HIV drug resistance mutations varies
regionally in Europe
M. Hofstra O_05
Patients with pre-existent NRTI- and NNRTI-resistance have
a higher risk to lose virological suppression under tenofovir/
emtricitabine/rilpivirine single tablet regimen
Excellent / Good
Average
Fair / poor
Interesting
88%
9%
3%
Relevance
77%
17%
6%
Excellent / Good
Average
Fair / poor
Interesting
83%
11%
6%
Relevance
72%
18%
10%
Excellent / Good
Average
Fair / poor
Interesting
79%
19%
2%
Relevance
66%
24%
10%
Excellent / Good
Average
Fair / poor
Interesting
97%
3%
0%
Relevance
70%
18%
12%
Performance
90%
5%
5%
D. Di Carlo O_06
Antiviral Activity of Tenofovir Alafenamide (TAF) against
HIV-1 Subtypes and Emergence of K65R
C. Callebaut O_07
Session 3: Abstract session - HBV- related
HBV Cure (Educational lecture in
collaboration with ESAR)
Massimo Levrero, MD, University of Rome
“La Sapienza”, Italy
Abstract-driven presentations:
Clinical impact of vaccine-escape HBsAg mutants in HBVinfected patients: high rate of atypical serological profiles
and increased level of viremia and transaminases
Excellent / Good
Average
Fair / poor
Interesting
79%
16%
5%
Relevance
63%
21%
16%
Excellent / Good
Average
Fair / poor
Interesting
74%
22%
4%
Relevance
62%
24%
14%
R. Salpini O_08
Immunosuppression-driven HBV Reactivation in Patients
with Resolved HBV Infection Correlates with a Relevant
Risk of Evolution Towards Active Chronic Infection and
Death
A. Battisti O_09
HBsAg immune-escape Mutations and Stop-Codons,
Circulating among European HBV-chronically infected
patients can impact on HBV transmission and disease
progression
Excellent / Good
Average
Fair / poor
Interesting
73%
22%
5%
Relevance
59%
24%
17%
Excellent / Good
Average
Fair / poor
Interesting
89%
10%
1%
Relevance
74%
18%
8%
Performance
88%
10%
2%
L. Colagrossi O_10
Session 4: Implementation of PrEP in Europe
Roadblocks to implementation
Pep Coll, MD, Irsi Caixa Foundation,
Barcelona, Spain
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
14
PARTICIPANTS’ FEEDBACK
Two cases of HIV drug resistance arising
after PrEP
Richard Harrigan, MD, BC Centre for
Excellence in HIV/AIDS, Canada
Community perspective
Rebekah Webb, MA, EATG, United Kingdom
Round Table discussion: experiences with
implementation of PrEP
Moderator: Charles Boucher
Excellent / Good
Average
Fair / poor
Interesting
89%
9%
3%
Relevance
75%
12%
13%
Performance
91%
9%
0%
Excellent / Good
Average
Fair / poor
Interesting
90%
9%
1%
Relevance
75%
14%
11%
Performance
95%
4%
1%
Excellent / Good
Average
Fair / poor
Interesting
93%
6%
1%
Relevance
76%
14%
11%
THURSDAY 26 MAY
HIV attachment inhibitors
Thomas Klimkait, PhD, University of Basel,
Switzerland
Excellent / Good
Average
Fair / poor
Interesting
96%
4%
0%
Relevance
78%
15%
7%
Performance
96%
4%
0%
Session 5: Special session - maintenance therapy
Maintenance Therapy - What is known
Esteban Martínez, MD, PhD, University of
Barcelona, Spain
Maintenance Therapy - What is the
scientific / virological rationale
Charles Boucher, MD, PhD, Erasmus
Medical Center, the Netherlands
Maintenance Therapy - What is the Future
Jonathan Schapiro, MD, Sheba Medical
Center, Israel
Excellent / Good
Average
Fair / poor
Interesting
100%
0%
0%
Relevance
87%
6%
6%
Performance
97%
3%
0%
Excellent / Good
Average
Fair / poor
Interesting
97%
3%
0%
Relevance
84%
10%
6%
Performance
97%
3%
0%
Excellent / Good
Average
Fair / poor
Interesting
100%
0%
0%
Relevance
94%
3%
3%
Performance
100%
0%
0%
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
15
PARTICIPANTS’ FEEDBACK
11TH INTERNATIONAL WORKSHOP ON HEPATITIS C: RESISTANCE AND NEW COMPOUNDS
Session 1:
Host-acting broad-spectrum antiviral
drugs from nature
Juana Díez, PhD, Universitat Pompeu Fabra,
Spain
How do we test for HCV RAVs (technologybased presentation)
Anita Howe, PhD, British Columbia Center
for Excellence for HIV/AIDS, Canada
Do we need surveillance for DAA
resistance: how to implement it
Stephanie Popping, MD, Erasmus MC, the
Netherlands
Excellent / Good
Average
Fair / poor
Interesting
77%
16%
6%
Relevance
63%
17%
20%
Performance
80%
10%
10%
Excellent / Good
Average
Fair / poor
Interesting
88%
13%
0%
Relevance
74%
23%
3%
Performance
81%
16%
3%
Excellent / Good
Average
Fair / poor
Interesting
87%
13%
0%
Relevance
72%
21%
7%
Performance
82%
14%
4%
Session 2:
What do we know about RAVs today
Francesca Ceccherini - Silberstein, PhD,
University of Rome ‘Tor Vergata’, Italy
Excellent / Good
Average
Fair / poor
Interesting
94%
6%
0%
Relevance
94%
3%
3%
Performance
94%
6%
0%
Excellent / Good
Average
Fair / poor
Interesting
89%
11%
0%
Relevance
88%
8%
4%
Excellent / Good
Average
Fair / poor
Interesting
97%
3%
0%
Relevance
82%
7%
11%
Abstract-driven presentations:
Substantial presence of natural NS3, NS5A and NS5B
HCV-resistance in real practice, and their impact on
direct-acting antiviral treatment in genotypes 1-4
V. Cento O_11
Characterization of Resistance-Associated Variants
at baseline and failure of All-Oral Antiviral Therapy of
Hepatitis C
A. Lai O_12
Session 3:
What do we need to know about RAVs
clinically
Stefan Zeuzem, MD, JW Goethe University
Hospital, Germany
Excellent / Good
Average
Fair / poor
Interesting
94%
6%
0%
Relevance
84%
13%
3%
Performance
87%
13%
0%
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
16
PARTICIPANTS’ FEEDBACK
Abstract-driven presentations:
Virological failures to DAA in real life show frequent
resistance associated variants and may require retreatment with unconventional regimens
Excellent / Good
Average
Fair / poor
Interesting
89%
11%
0%
Relevance
88%
4%
8%
Excellent / Good
Average
Fair / poor
V. C. Di Maio O_13
Treatment emergent variants to combined direct antiviral
agents therapy against hepatitis C virus
F. Garcia O_14
Total HIV DNA increases in lymphomonocytes of HCV/HIV
co-infected patients during and after DAA treatment
I. Abbate O_15
Interesting
93%
7%
0%
Relevance
88%
8%
4%
Excellent / Good
Average
Fair / poor
Interesting
76%
19%
5%
Relevance
75%
10%
15%
Excellent / Good
Average
Fair / poor
Interesting
100%
0%
0%
Relevance
92%
4%
4%
Performance
100%
0%
0%
Excellent / Good
Average
Fair / poor
100%
0%
0%
FRIDAY 27 MAY
Session 6: Remaining challenges in the optimal use of
boosted PIs
Pro-con Debate: Role of PIs in first line therapy
PI are obsolete in first line
Anna Maria Geretti, MD, PhD, University of
Liverpool, UK
PI remain important option for first line
Linos Vandekerckhove, MD, PhD, University
Hospital Gent, Belgium
Improving PI drug resistance scores
Jens Verheyen, MD, University Clinic Essen,
Germany
Interesting
Relevance
92%
4%
4%
Performance
88%
12%
0%
Excellent / Good
Average
Fair / poor
Interesting
96%
4%
0%
Relevance
87%
4%
9%
Performance
100%
0%
0%
Excellent / Good
Average
Fair / poor
Interesting
100%
0%
0%
Relevance
86%
9%
5%
Performance
100%
0%
0%
Session 7: HIV cure strategies
Diagnostic Assays
Javier Martinez Picado, PhD, Irsi Caixa
Foundation, Barcelona, Spain
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
17
PARTICIPANTS’ FEEDBACK
Abstract-driven presentations:
Ex vivo determination of stem cell transplantation graftversus-HIV reservoir effects
L. Hogan O_16
Clonal Integration Site Frequency and Replication
Competent Virus in Patients on ART
L. Vandekerckhove O_17
Boston Project
Timothy Henrich, MD, UCSF, USA
Excellent / Good
Average
Fair / poor
Interesting
90%
5%
5%
Relevance
74%
11%
15%
Excellent / Good
Average
Fair / poor
Interesting
89%
11%
0%
Relevance
76%
12%
12%
Excellent / Good
Average
Fair / poor
Interesting
95%
5%
0%
Relevance
82%
9%
9%
Performance
95%
5%
0%
Excellent / Good
Average
Fair / poor
Interesting
89%
11%
0%
Relevance
67%
22%
11%
Abstract-driven presentations:
Viral dynamics and post-mortem analysis of HIV-1
Reservoir after Allogeneic Transplantation using Stem
Cells with a nonfunctional CCR5 (CCR5 -d32) co-receptor
K. Bosman O_18
Treatment of HIV and acute myeloid leukemia by
allogeneic CCR5-d32 blood stem cell transplantation
E. Knops O_19
Breakthrough of preexisting X4-tropic HIV after
allogeneic stem-cell transplantation
J. Verheyen O_20
Excellent / Good
Average
Fair / poor
Interesting
89%
11%
0%
Relevance
61%
28%
11%
Excellent / Good
Average
Fair / poor
Interesting
89%
11%
0%
Relevance
72%
17%
11%
Panel Discussion
Members: Javier Martinez Picado, Timothy Henrich, Rolf
Kaiser, Monique Nijhuis and Annemarie Wensing
Excellent / Good
Average
Fair / poor
Interesting
94%
6%
0%
Relevance
69%
25%
6%
GUIDED POSTER TOUR
(Very much) agree
Neutral
(Very much) disagree
Guided poster tour was a valuable addition
83%
13%
4%
The posters selected for the tour were relevant
88%
8%
4%
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
18
PARTICIPANTS’ FEEDBACK
ORGANIZATION
Excellent/good
Average
Fair/poor
Content of electronic announcements
86%
8%
6%
Frequency of electronic announcements
84%
14%
3%
Information on coference website
74%
20%
6%
Online registration process
76%
19%
5%
Online abstract submission process
84%
12%
4%
Meeting venue
84%
16%
0%
Food & Beverage
89%
8%
3%
Audiovisuals
78%
14%
8%
Onsite logistics
86%
11%
3%
Service level of Conference Secretariat
89%
11%
0%
PUBLICITY
Attention was drawn to this meeting by:
I a m returning
pa rti cipant
30%
Col l eague / word of
mouth
17%
Invi te from the
i ndustry
2%
Influenced to attend this meeting by:
Experience
CME
Accreditation from previous
edtions
3%
14%
VE webs ite
19%
VE-email
a nnouncement
16%
Invi te by fa culty
members
12%
Location
6%
Reg.
fee
2%
Opportunity to
meet with
colleagues
19%
Meeting
description
19%
Scientific
program
37%
VE i nvi tation letter
Fl yer a t other 3%
meetings
1%
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
19
MEETING DEMOGRAPHICS
NUMBER OF PARTICIPANTS
In 2015 this meeting had 287 participants from 40 countries. Largest groups were from Italy (85), Germany (16),
Belgium(16) and Russia (16).
The geographical distribution of participants is as follows:
Australia2
Estonia1
Mexico5
Spain10
Bangladesh2
Finland4
Montenegro2
Sweden4
Belarus1
France6
Nepal1
Switzerland2
Belgium16
Germany16
Norway6
The Netherlands
Brazil1
Greece4
Poland4
Turkey3
Bulgaria1
Hungary2
Portugal12
Ukraine11
Canada10
Israel2
Romania1
United Kingdom
Chile5
Italy85
Russia16
USA6
Cyprus1
Latvia2
Saudi Arabia
Czech Republic
1
Lithuania5
Serbia2
Denmark5
Luxembourg2
Slovenia1
14
11
2
PROFESSIONAL BACKGROUND
Main activity
Mainly employed by:
Virologist
1%
PhD
Student
8%
Other
16%
Clinician
31%
Lab technician
5%
NGO
Government 2%
5%
Other
11%
Pharma
6%
University
48%
Hospital
28%
Researcher
39%
Area of expertise:
Other
3%
ID
15%
Hepatitis
35%
HIV
47%
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
20
CONCLUSION
The overall opinion of the meeting was very positive, as can be deducted from the above scores. Participants were satisfied
with the scientific content of the workshop as well as with the logistics and the format of the program. The Organizing
Committee and the Organizing Secretariat are very pleased with the evaluation results of this workshop. The success and
importance of this workshop have underlined the need for continuation. The 15th edition of the European Meeting on HIV &
Hepatitis - Treatment Strategies & Antiviral Drug Resistance is scheduled to take place on 7 - 9 May 2017 in Rome, Italy.
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
21
LIST OF PARTICIPANTS
Last name, name
Institute
Country
Abbate, Isabella
Istituto Nazionale per le Malattie Infettive "Lazzaro
Spallanzani" Roma
Italy
Abreu, Ricardo
HPHispano-Matosinhos
Portugal
Acevedo Muñoz, William
Hospital de Enfermedades infecciosas Dr Lucio Cordova
Chile
Adams, Philipp
Luxembourg institute of health
Luxembourg
Afani, Alejandro
University of Chile
Chile
Ahmed, Nursarat
Gazi Medical college and Hospital
Bangladesh
Aladdin, Hassan
Gilead
Denmark
Albert, Jan
Karolinska Institutet
Sweden
Albini, Laura
Gilead Sciences
Italy
Alexiev, Ivailo
Nat. Center of Infectious and Parasitic Diseases
Bulgaria
Ali, Batool
East Jeddah Hospital
Saudi Arabia
Alteri, Claudia
University of Rome Tor Vergata
Italy
Amato, Maurizio
ViiV Healthcare
Italy
Andre, Gomes
Hospital Garcia de Orta
Portugal
Antonucci, FrancescoPaolo
University of Rome Tor Vergata
Italy
Aragri, Marianna
University of Rome Tor Vergata
Italy
Armenia, Daniele
University of Rome Tor Vergata
Italy
Avanzi, Valeria Miranda
Universidade Federal do Paraná
Brazil
Bak, Narin
Royal Adelaide Hospital
Australia
Bakken Kran, Anne-Marte
Oslo University Hospital
Norway
Bakó, Fruzsina
St.István és St.László Kórház
Hungary
Baldanti, Fausto
IRCCS Policlinico S. Matteo
Italy
Bandera, Alessandra
San Gerardo Hospital
Italy
Bang, Didi
Statens Serum Institut
Denmark
Bannert, Norbert
Robert Koch-Institut
Germany
Barbaliscia, Silvia
University of Rome Tor Vergata
Italy
Baril, Jean-Guy
Clinique du Quartier Latin
Canada
Bartolini, Barbara
Istituto Nazionale per le Malattie Infettive "Lazzaro
Spallanzani" Roma
Italy
Battisti, Arianna
University of Rome Tor Vergata
Italy
Behrens, Georg
Medical School Hannover
Germany
Beloukas, Apostolos
Institute of Infection and Global Health
United Kingdom
Beltrán, Carlos
Chilean AIDS Group
Chile
Berno, Giulia
University of Rome Tor Vergata
Italy
Bertoli, Ada
University of Rome Tor Vergata
Italy
Berzina, Ilze
Riga Eastern Clinical University Hospital, Infectology
Center
Latvia
Bobkova, Marina
Ivanovsky Institute of Virology Gamaleya Center for
Epidemiology and Microbiology
Russia
Boccuto, Adele
UNIVERSITA' DI SIENA- Policlinico Le Scotte
Italy
Bocket, Laurence
CHRU Lille
France
Boggia, Nadia
ViiV Healthcare
Italy
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
22
Bon, Isabella
Università di Bologna
Italy
Bondar, Borys
AbbVie
Ukraine
Bosman, Kobus
University Medical Center Utrecht UMCU
The Netherlands
Boucher, Charles
Erasmus Medical Center
The Netherlands
Bozhok, Halyna
Kirovograd AIDS center
Ukraine
Braun, Patrick
Insto GmbH
Germany
Brunetta, Jason
Maple Leaf Medical Clinic
Canada
Bruzzone, Bianca
University of Genoa
Italy
Caligiuri, Patrizia
Irccs Azienda Univ. Osp. San Martino
Italy
Callebaut, Christian
Gilead
USA
Callegaro, Annapaola
Ospedali Riuniti di Bergamo Hospital Papa Giovanni XXIII
Italy
Camacho, Ricardo
KU Leuven
Belgium
Cardoso, Luis
Gilead Sciences
Portugal
Carioti, Luca
University of Rome Tor Vergata
Italy
Carta, Stefania
University of Rome Tor Vergata
Italy
Carvalho, Margarida Maria
CH Vila Nova Gaia
Portugal
Ceccherini-Silberstein, Francesca
University of Rome Tor Vergata
Italy
Cento, Valeria
University of Rome Tor Vergata
Italy
Chen, Alan
The Ohio State University
USA
Chernova, Oksana
Tolyatti City Clinical Hospital No. 5
Russia
Chevaliez, Stéphane
Hôpital Henri Mondor, Université Paris XII
France
Chulanov, Vladimir
Central Research Institute of Epidemiology
Russia
Cid Silva, Purificacion
Gilead Sciences
Spain
Cinite, Ingrida
GlaxoSmithKline
Latvia
Circhetta, Simona
Gilead Sciences
Italy
Colagrossi, Luna
University of Rome Tor Vergata
Italy
Coll, Pep
Hospital Universitari Germans Trias i Pujol
Spain
Craxì, Antonio
DIBIMIS, University of Palermo
Italy
Cuomo, Nunzia
Aorn ospedali dei colli - Cotugno
Italy
Cuypers, Lize
Rega Institute for Medical Research
Belgium
Damele, Francesco
Janssen
Italy
D'Angelo, Giulia Maria
University of Rome Tor Vergata
Italy
De Jorge, Rocio
ViiV Healthcare
Spain
De Luca, Andrea
University of Catania Azienda Ospedaliera Senese
Italy
Debaisieux, Laurent
ULB-Erasme
Belgium
Demecheleer, Els
University Hospital Gent
Belgium
Demetriades, Ioannis
Larnaca General Hospital
Cyprus
Depypere, Melissa
UZ Brussel
Belgium
Devaux, Carole
CRP-Santé
Luxembourg
Di Carlo, Daniele
Sapienza - Università di Roma
Italy
Di Carlo, Domenico
University of Rome Tor Vergata
Italy
Di Maio, Velia Chiara
University of Rome Tor Vergata
Italy
Diez, Juana
Univerity Pompeu Fabra
Spain
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
23
Dorenberg, Dagny Haug
Norwegian Institute of Public Health
Norway
Döring, Matthias
Max Planck Institute for Informatics
Germany
Dressler, Stephan
EATG - European AIDS Treatment Group
Belgium
Dupanovic, Brankica
Institute of Public Health Montenegro
Montenegro
Dvorakova, Katerina
GSK
Czech Republic
Dyda, Tomasz
Hospital for Infectious Diseases
Poland
Ehret, Robert
BAG MVZ mib AG & Kollegen GbR Medizinisches Labor Dr.
Berg
Germany
Fabeni, Lavinia
I.N.M.I. Lazzaro Spallanzani
Italy
Fabietti, Giulio
ViiV Healthcare
Italy
Falasca, Francesca
Sapienza - Università di Roma
Italy
Farabegoli, Patrizia
AUSL Cesena
Italy
Fedele, Valentina
University of Rome Tor Vergata
Italy
Feinberg, Joshua
Copenhagen University Hospital Rigshospitalet
Denmark
Fernandes, Magda
H.Sra.Oliveira-Guimarães
Portugal
Ferreira, Mafalda
Instituto Superior de Ciências da Saúde Egas Moniz
Portugal
Ferrer, Pablo
Universidad de Chile
Chile
Ferrinho, Diogo
Gilead Sciences Europe
United Kingdom
Fimiani, Caterina
Policlinico Umberto I
Italy
Fini, Vanessa
University of Rome Tor Vergata
Italy
Floe, Reinhardt
GlaxoSmithKline
Norway
Fokam, Joseph
University of Rome Tor Vergata
Italy
Fonager, Jannik
Statens Serum Institut
Denmark
Forbici, Federica
University of Rome Tor Vergata
Italy
Franzese, Sonia
Gilead Sciences
Italy
Fraser, Chris
Cool Aid Clinic
Canada
Galizzi, Nadia
Univarsità Vita-Salute - Ospedale San Raffaele Milano
Italy
Garcia, Federico
CHU Granada; Centro PTS-San Cecilio. Inst Inv
Biosanitaria Ibs-Granada.
Spain
Gardziuliene, Gabija
Glaxo Smith Kline
Lithuania
Gaytán Martínez, Jesús Enrique
National Medical Center "La Raza", Mexico
Mexico
Geretti, Anna Maria
University of Liverpool Institute of Infection and Global
Health
United Kingdom
Giannella, Sara
University of Rome Tor Vergata
Italy
Giannini, Alessia
UNIVERSITA' DI SIENA - Policlinico Le Scotte
Italy
Gomes, Perpetua
Centro Hospitalar de Lisboa Ocidental
Portugal
Gori, Caterina
University of Rome Tor Vergata
Italy
Gunduz, Alper
Sisli Etfal Training and Research Hospital
Turkey
Haartsen, Maxim
ViiV Healthcare
United Kingdom
Hammer, Janniche
Gilead Sciences
Norway
Harrigan, Richard
BC Centre for Excellence in HIV/AIDS
Canada
Hauser, Andrea
Robert Koch-Institut
Germany
Hawkes, Jennifer
Northern Health
Canada
Henrich, Timothy
University of California, San Francisco
USA
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
24
Hofstra, Marije
University Medical Center Utrecht UMCU
The Netherlands
Hogan, Louise
UCSF
USA
Howe, Anita
Vancouver Coastal Health Authority
Canada
Jevtovic, Djordje
Institute for Infectious and Tropical Diseases
Serbia
Kaiser, Rolf
University of Cologne
Germany
Kanestrøm, Anita
Norwegian Institute of Public Health
Norway
Kapusta, Margaryta
Mykolaiv Regional State Administration
Ukraine
Kausas, Aidas
Siauliai County Hospital
Lithuania
Kazennova, Elena
Ivanovsky Institute of Virology Gamaleya Center for
Epidemiology and Microbiolog
Russia
Khromova, Irina
Republican Center for Prevention and Control of AIDS and
Infectious Diseases
Russia
Klein, Alex
Mount Sinai Hospital
Canada
Klimkait, Thomas
University of Basel
Switzerland
Knezevic, Olgica
Institute of Public Health Montenegro
Montenegro
Knops, Elena
University of Cologne
Germany
Koenig, Bettina
Abbvie
Germany
Kostaki, Evangelina
University of Athens
Greece
Kwa, David
Onze Lieve Vrouwe Gasthuis
The Netherlands
Kyrychenko, Tatyana
Ukrainian Medical Stomatological Academy
Ukraine
Kyryliuk, Olga
Abbvie
Ukraine
Laga, Vita
Ivanovsky Institute of Virology Gamaleya Center for
Epidemiology and Microbiology
Russia
Lai, Alessia
University of Milan
Italy
Lapovok, Ilya
Central Research Institute for Epidemiology
Russia
Lennerstrand, Johan
Uppsala University
Sweden
Lettinga, Kamilla
Onze Lieve Vrouwe Gasthuis
The Netherlands
Levrero, Massimo
University La Sapienza
Italy
Lichtner, Miriam
Sapienza University of Rome
Italy
Liitsola, Kirsi
National Institute for Health and Welfare
Finland
Lipsi , Maria Rosaria
OSPEDALI RIUNITI - FOGGIA
Italy
Loginova, Tetyana
Narcological Hospital Socialtherapy
Ukraine
Longo, Serena
Università di Bologna
Italy
Louagie, Philippe
ViiV Healthcare
Belgium
Louis, Isabelle
University Bordeaux Inserm U897- Isped
France
Loveday, Clive
ICVC Charitable Trust
United Kingdom
Lübke, Nadine
Institute of Virology
Germany
Lynn, Amber
Alberta Health Services
Canada
Maijgren Steffensson, Catharina
Gilead Sciences Sweden AB
Sweden
Marascio, Nadia
University "Magna Graecia"
Italy
Martínez Picado, Javier
Fundacio irsiCaixa
Spain
Martinez, Esteban
Hospital Clinic Barcelona
Spain
Martiushova, Inna
Tula Regional Hospital
Russia
Mascia, Claudia
Sapienza - Università di Roma
Italy
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
25
Mata-Marín, José Antonio
Centro Medico Nacional "La Raza"
Mexico
Matsiyeuskaya, Natallia
Grodno State Medical University
Belarus
Matulionyte, Raimonda
Vilnius University
Lithuania
Mazzuti, Laura
Sapienza - Università di Roma
Italy
Meini, Genny
Università degli Studi di Siena
Italy
Micheli, Valeria
University Hospital L. Sacco
Italy
Mölkänen, Tomi
GlaxoSmithKline
Finland
Mor, Orna
Sheba Medical Center
Israel
Mortier, Virginie
University Hospital Gent
Belgium
Mudrikova, Tatiana
University Medical Center Utrecht UMCU
The Netherlands
Nielsen, Emil Eik
Copenhagen University Hospital Rigshospitalet
Denmark
Nieman, An-Emmie
St Elisabeth Ziekenhuis
The Netherlands
Nijhuis, Monique
University Medical Center Utrecht UMCU
The Netherlands
Ojha, Chet
Government of Nepal
Nepal
Oliveira, Celia
Hospital de Aveiro
Portugal
Oosterlaken, Tom
Hologic
The Netherlands
Palandri, Lucia
University of Rome Tor Vergata
Italy
Paolucci, Stefania
IRCCS Policlinico S. Matteo
Italy
Paraskevis, Dimitrios
University of Athens
Greece
Parczewski, Milosz
Pomeranian Medical University
Poland
Paredes, Roger
IrsiCaixa Foundation
Spain
Paricio, Antonio
Hospital Francisco De Borja De Gandia
Spain
Paul, Miriam
Macquarie University
Australia
Pereira, Rui
Hospital de Faro
Portugal
Perno, Carlo-Federico
University of Rome Tor Vergata
Italy
Pesic Pavlovic, Ivana
Clinical Center of Serbia
Serbia
Petrovska, Olena
Zaporizhya AIDS center
Ukraine
Petry, Ralph
Abbvie Deutschland GmbH & Co KG
Germany
Piermatteo, Lorenzo
University of Rome Tor Vergata
Italy
Pineda-Peña, Andrea Clemencia
KU Leuven
Belgium
Pirazolli, Antonella
ViiV Healthcare
United Kingdom
Poljak, Mario
University of Ljubljana Medical Faculty
Slovenia
Pompei, Marco
Merck Sharp and Dohme
Belgium
Popping, Stephanie
Erasmus Medical Center
The Netherlands
Poretskova, Elena
R-Pharm
Russia
Posthumus-Plantinga, Alice
Virology Education
The Netherlands
Poveda, Eva
INIBIC-Complejo Hospitalario Universitario de A Coruña
Spain
Poveda, Jean-Dominique
Laboratoire CERBA
France
Prodanova, Kseniia
Center of prevention and control of AIDS
Russia
Quercia, Romina
ViiV Healthcare
United Kingdom
Rahman, Nawshad Muhammad
Wahidur
Gazi Medical college and Hospital
Bangladesh
Rappazzo, Emanuela
San Martino Hospital University of Genoa
Italy
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
26
Robinson, Chris
Gilead Sciences
United Kingdom
Rodriguez-Diaz, Roberto
Instituto Nacional de Ciencias Médicas y Nutrición
Mexico
Rogatto, Felipe
Gilead Sciences
United Kingdom
Roger Schmeltz, Julien
Gilead Sciences
France
Rosas, Antonio
Pharma Investi de Chile Ss. A.
Chile
Rossetti, Barbara
Clinic of Infectious Diseases, AOUS
Italy
Roxo, Joao
HOSPITAL DOS CAPUCHOS
Portugal
Rozera, Gabriella
Istituto Nazionale per le Malattie Infettive "Lazzaro
Spallanzani" Roma
Italy
Rubin, Gary
University of Toronto
Canada
Ruelle, Jean
UC Louvain
Belgium
Ruggiero, Tina
Amedeo di Savoia Hospital
Italy
Sabinina, Olena
Poltava AIDS center
Ukraine
Sakalauskiene, Ugne
Central Prison Hospital
Lithuania
Saladini, Francesco
University of Siena
Italy
Salpini, Romina
University of Rome Tor Vergata
Italy
Santangelo, Rosaria
Catholic University Del Sacro Cuore Institute of Clinical
Infectious Diseases
Italy
Santoro, Maria
University of Rome Tor Vergata
Italy
Sarmometov, Evgenii
Perm Regional Centre for the Fight against AIDS and
infectious diseases
Russia
Sayan, Murat
Kocaeli University
Turkey
Schaffer, Sven
Hologic
Germany
Schapiro, Jonathan
Sheba Medical Center
Israel
Schütze, Marcel
MVZ mib medizinisches Infektiologiezentrum Berlin AG
Germany
Scutari, Rossana
University of Rome Tor Vergata
Italy
Shevchenko, Olga
Dnipropetrovsk Medical Academy
Ukraine
Shostakovych-Koretskaya, Liudmyla Dnipropetrovsk Medical Academy
Ukraine
Sikut, Rein
GlaxoSmithKline
Estonia
Silva, Luis
H. Fernando Fonseca
Portugal
Sönnerborg, Anders
Karolinska Institutet
Sweden
Sorbo, Maria Chiara
University of Rome Tor Vergata
Italy
Stanczak, Janusz
Hospital for Infectious Diseases
Poland
Starikova, Irina
Republican Center for Prevention and Control of AIDS and
Infectious Diseases
Russia
Stasishkis, Tatiana
Republican Center for Prevention and Control of AIDS and
Infectious Diseases
Russia
Stazi, Francesca
University of Rome Tor Vergata
Italy
Stefanova, Ina
ViiV Healthcare
Canada
Stene-Johansen, Kathrine
Norwegian Institute of Public Health
Norway
Stepanova, Elena
Republican Center for Prevention and Control of AIDS and
Infectious Diseases
Russia
Sterrantino, Gaetana
Azienda Ospedaliera Universitaria Careggi
Italy
Sticchi, Laura
University of Genoa
Italy
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
27
Sutinen, Jussi
Helsinki University Hospital
Finland
Tau, Pamela
University Hospital L. Sacco
Italy
Tavares, Francisca
Gilead Sciences
Portugal
Tudor, Ana Maria
Institute for Infectious Disease M. Bals Matei
Romania
Ujhelyi, Eszter
St.István és St.László Kórház
Hungary
Underwood, Mark
GlaxoSmithKline
USA
Vandamme, Anne-Mieke
Katholieke Univ. Leuven Rega Institute for Medical
Research
Belgium
Vandekerckhove, Linos
Universitair Ziekenhuis Gent UZ
Belgium
Vandercam, Bernard
UCLouvain
Belgium
Vanhouteghem, Hilde
AZ Maria Middelares
Belgium
Varna, Klaidas
Abbvie
Lithuania
Vatteroni, Marialinda
Azienda Ospedaliera Universitaria Pisana
Italy
Verheyen, Jens
Universitätsklinikum Essen
Germany
Vicenti, Ilaria
University of Siena
Italy
Villa, Giovanni
University of Liverpool Institute of Infection and Global
Health
United Kingdom
Vincenti, Donatella
Istituto Nazionale per le Malattie Infettive "Lazzaro
Spallanzani" Roma
Italy
Vuorte, Juha
Gilead Sciences Finland
Finland
Wali, Ghassan
King Faisal Specialist Hospital and Research Centre
Saudi Arabia
Walter, Hauke
Germany
Webb, Rebekah
EATG european aids treatment group
Belgium
Weijer, Sebastiaan
MC/groep MC Zuiderzee
The Netherlands
Weiser Smeke, Ariane Estrella
Anahuac University, Medicine school, Mexico city, Mexico
Mexico
Wensing, Annemarie
University Medical Center Utrecht UMCU
The Netherlands
White, Kirsten
Gilead Sciences
USA
Widera, Marek
Institute of Virology, University Hospital of Essen
Germany
Yalcinkaya Kezban Tulay, Kezban
Tulay
National Public Health Institution of Turkey
Turkey
Yurchuk, Sergey
Regional Clinical Hospital of Infectious Diseases
Russia
Zabek, Piotr
Hospital for Infectious Diseases
Poland
Zaccarelli, Mauro
INMI L Spallanzani
Italy
Zadorozhna, Kateryna
Kharkiv AIDS center
Ukraine
Zanussi, Stefania
Oncology Reference Centre
Italy
Zazzi, Maurizio
University of Siena
Italy
Zeuzem, Stefan
JW Goethe University Hospital
Germany
Zingg, Maurice
University of Basel
Switzerland
EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance
25 - 27 May 2016, Rome, Italy
28